Meeting
2019 ASCO Annual Meeting
Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE).
Authors
Shukui Qin
PLA Cancer Center of Bayi Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China
Shukui Qin , Jiafu Ji , Rui-hua Xu , Wei Wang , Yong Tang , Feng Bi , Jin Li , Kang Wang , Jianming Xu , Qingxia Fan , Wuyun Su , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT01839500
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4025)
DOI
10.1200/JCO.2019.37.15_suppl.4025
Abstract #
4025
Poster Bd #
130
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Clinical significance of intratumoral HER2 heterogeneity (IHH) using endoscopic biopsy specimens in patients with HER2-positive gastric cancer (GC) who received T-mab-based chemotherapy.
First Author: Shusuke Yagi
Poster
2019 Gastrointestinal Cancers Symposium
![A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.](https://d201v5jt9ylckg.cloudfront.net/235/14138/168794/168794_poster_pv.jpg)
A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
First Author: Kohei Shitara
Poster
2018 ASCO Annual Meeting
Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).
First Author: Whitney Paige Kirschbrown
Poster
2015 Gastrointestinal Cancers Symposium
Lapatinib combined with ECF/x as first-line metastatic gastric cancer (GC) according to HER2 and EGFR status: A randomized placebo controlled phase II (EORTC 40071).
First Author: Markus Hermann Moehler